人类免疫缺陷病毒1型疫苗研发中的挑战。
Challenges in the development of an HIV-1 vaccine.
作者信息
Barouch Dan H
机构信息
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
出版信息
Nature. 2008 Oct 2;455(7213):613-9. doi: 10.1038/nature07352.
Abstract
The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a critically important global health priority. Despite recent advances in our understanding of HIV-1 pathogenesis and immunology, however, major scientific obstacles remain. Prototype HIV-1 vaccine candidates aimed at eliciting humoral and cellular immune responses have so far failed to protect against HIV-1 infection or to reduce viral loads after infection in clinical efficacy studies. A renewed and coordinated commitment to basic discovery research, preclinical studies and clinical trials will therefore be required to overcome the hurdles currently facing the field. Here I review key challenges and future prospects in the quest to develop a prophylactic HIV-1 vaccine.
摘要
开发一种安全有效的人类免疫缺陷病毒（HIV）-1疫苗是全球卫生领域至关重要的优先事项。然而，尽管我们对HIV-1发病机制和免疫学的理解最近取得了进展，但主要的科学障碍仍然存在。旨在引发体液免疫和细胞免疫反应的HIV-1疫苗候选原型在临床疗效研究中迄今未能预防HIV-1感染或降低感染后的病毒载量。因此，需要重新做出协调一致的承诺，开展基础发现研究、临床前研究和临床试验，以克服该领域目前面临的障碍。在此，我将回顾在开发预防性HIV-1疫苗过程中的关键挑战和未来前景。
相似文献
1
Challenges in the development of an HIV-1 vaccine.人类免疫缺陷病毒1型疫苗研发中的挑战。
Nature. 2008 Oct 2;455(7213):613-9. doi: 10.1038/nature07352.
2
HIV-1 vaccine development after STEP.STEP 后 HIV-1 疫苗的开发。
Annu Rev Med. 2010;61:153-67. doi: 10.1146/annurev.med.042508.093728.
3
Current strategies and limitations of HIV vaccines.HIV疫苗的当前策略与局限性
Curr Opin Investig Drugs. 2010 Feb;11(2):192-202.
4
HIV vaccine: hopes and hurdles.HIV 疫苗：希望与挑战。
Drug Discov Today. 2011 Nov;16(21-22):948-56. doi: 10.1016/j.drudis.2011.08.013. Epub 2011 Aug 26.
5
Prospects for vaccine protection against HIV-1 infection and AIDS.预防HIV-1感染和艾滋病的疫苗保护前景。
Annu Rev Immunol. 2002;20:73-99. doi: 10.1146/annurev.immunol.20.081501.094854. Epub 2001 Oct 4.
6
Accelerating HIV-1 Vaccine Efficacy Trials.加速 HIV-1 疫苗功效试验。
Cell. 2014 Nov 20;159(5):969-972. doi: 10.1016/j.cell.2014.10.046.
7
Human immunodeficiency virus antibodies and the vaccine problem.人类免疫缺陷病毒抗体与疫苗问题。
J Intern Med. 2014 May;275(5):444-55. doi: 10.1111/joim.12225.
8
Tiny steps towards an HIV vaccine.向艾滋病疫苗迈进的微小步伐。
Nature. 2010 Jul 15;466(7304):S8. doi: 10.1038/nature09238.
9
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.用于 HIV-1 预防的疫苗和广泛中和抗体。
Annu Rev Immunol. 2020 Apr 26;38:673-703. doi: 10.1146/annurev-immunol-080219-023629.
10
No acquisition: a new ambition for HIV vaccine development?无获得：HIV 疫苗研发的新目标？
Curr Opin Virol. 2011 Oct;1(4):246-53. doi: 10.1016/j.coviro.2011.07.005.
引用本文的文献
1
Multiplexed Epitope Mapping of HIV-1 Neutralizing Antibodies by Coupling Chemical Labeling of Cysteines to Deep Sequencing.通过将半胱氨酸化学标记与深度测序相结合对HIV-1中和抗体进行多重表位作图
Methods Mol Biol. 2025;2937:229-241. doi: 10.1007/978-1-0716-4591-8_14.
2
mRNA Vaccine Technology Beyond COVID-19.新冠疫情之后的mRNA疫苗技术
Vaccines (Basel). 2025 May 31;13(6):601. doi: 10.3390/vaccines13060601.
3
Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat.利用机器学习提高靶向gp41 N-七肽重复序列的HIV-1抗体的中和效力。
ACS Chem Biol. 2025 Jul 18;20(7):1470-1480. doi: 10.1021/acschembio.5c00035. Epub 2025 Jun 20.
4
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120.基于免疫信息学的针对HIV-1 gp120的多表位mRNA疫苗的设计与评估
Front Immunol. 2025 May 13;16:1480025. doi: 10.3389/fimmu.2025.1480025. eCollection 2025.
5
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.人类免疫缺陷病毒1型疫苗研究的进展与挑战：全面综述
Vaccines (Basel). 2025 Jan 31;13(2):148. doi: 10.3390/vaccines13020148.
6
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.从人类HIV-1疫苗试验参与者中分离出的聚糖反应性抗体表现出广泛的病原体交叉反应性。
bioRxiv. 2025 Jan 20:2025.01.17.633475. doi: 10.1101/2025.01.17.633475.
7
Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection.一种HIV-1中和抗体提供的针对黏膜感染的杀菌免疫机制。
PLoS Pathog. 2024 Dec 26;20(12):e1012777. doi: 10.1371/journal.ppat.1012777. eCollection 2024 Dec.
8
Prophylactic and therapeutic vaccine development: advancements and challenges.预防性和治疗性疫苗的研发：进展与挑战。
Mol Biomed. 2024 Nov 11;5(1):57. doi: 10.1186/s43556-024-00222-x.
9
Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.药物递送的生物屏障以及针对HIV、胰腺癌和甲型/乙型血友病的创新治疗方法的开发
Pharmaceutics. 2024 Sep 13;16(9):1207. doi: 10.3390/pharmaceutics16091207.
10
HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence.HIV疫苗接种：探寻变革性突破之路——当前证据综述
Health Sci Rep. 2024 Sep 23;7(9):e70089. doi: 10.1002/hsr2.70089. eCollection 2024 Sep.
本文引用的文献
1
HIV vaccine research: the way forward.HIV疫苗研究：前进之路。
Science. 2008 Jul 25;321(5888):530-2. doi: 10.1126/science.1161000.
2
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.非人灵长类动物模型与默克公司HIV-1疫苗在人体试验中的失败
Nat Med. 2008 Jun;14(6):617-21. doi: 10.1038/nm.f.1759.
3
25 years of HIV.艾滋病流行25年。
Nature. 2008 May 15;453(7193):289-90. doi: 10.1038/453289a.
4
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.一种复制缺陷型5型腺病毒HIV-1 B亚型gag/pol/nef疫苗在健康成年人中的安全性和免疫原性。
Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.
5
Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation.通过体内电穿孔将抗原呈递细胞募集至接种部位并增强1型人类免疫缺陷病毒DNA疫苗的免疫原性。
J Virol. 2008 Jun;82(11):5643-9. doi: 10.1128/JVI.02564-07. Epub 2008 Mar 19.
6
Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.重组腺病毒载体和异源初免-加强免疫方案在恒河猴中引发的细胞免疫反应的强度和表型。
J Virol. 2008 May;82(10):4844-52. doi: 10.1128/JVI.02616-07. Epub 2008 Mar 12.
7
T-cell quality in memory and protection: implications for vaccine design.记忆与保护中的T细胞质量：对疫苗设计的启示
Nat Rev Immunol. 2008 Apr;8(4):247-58. doi: 10.1038/nri2274. Epub 2008 Mar 7.
8
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.一种被广泛中和抗体靶向的HIV-1 gp41融合中间态。
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44. doi: 10.1073/pnas.0800255105. Epub 2008 Mar 5.
9
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.一种HIV-1 C亚型DNA初免、NYVAC加强疫苗方案可诱导可靠、多功能且持久的T细胞应答。
J Exp Med. 2008 Jan 21;205(1):63-77. doi: 10.1084/jem.20071331. Epub 2008 Jan 14.
10
HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.HIV-1广泛中和抗体从病毒膜上一个扭结的gp41胞外域区域提取其表位。
Immunity. 2008 Jan;28(1):52-63. doi: 10.1016/j.immuni.2007.11.018.
Zotero 插件